Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus delbrueckii subsp. bulgaricus LB42
- Development stage
- Unknown
- Lead developer
- Punature Food Ingredients
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus delbrueckii subsp. bulgaricus LB42 is a probiotic bacterial strain traditionally used as a yogurt starter. It has been evaluated for its safety and functional benefits in healthy adults, demonstrating the ability to improve gastrointestinal function, enhance immune responses (specifically IgA and IgG), and improve sleep quality. Mechanistically, LB42 adheres to intestinal epithelial cells, modulates the gut microbiota by enriching short-chain fatty acid (SCFA)-producing genera like Lachnospira and Parabacteroides, and suppresses pro-inflammatory taxa such as Enterococcus and Fusobacterium. Clinical evidence indicates it reduces gastrointestinal symptoms and fecal calprotectin levels, supporting its use as a multifunctional food supplement for host immunity and microbial balance.
- Other names
- Lactobacillus delbrueckii subsp. bulgaricus LB42
02
Targets
IgA (Immunoglobulin A)
Beyond the preview
Go deeper on Lactobacillus delbrueckii subsp. bulgaricus LB42.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus delbrueckii subsp. bulgaricus LB42.